A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 [lapatinib; Tyverb; GlaxoSmithKline] and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer.

Trial Profile

A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 [lapatinib; Tyverb; GlaxoSmithKline] and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 Results of pooled analysis (n=1902) from this and two other trials (see profile 1409 and 2335) published in the Journal of Clinical Oncology
    • 03 Jun 2014 Results (meta-analysis) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 11 May 2010 Actual patient number changed from 399 to 408 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top